1. Home
  2. CAE vs IBRX Comparison

CAE vs IBRX Comparison

Compare CAE & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CAE Inc.

CAE

CAE Inc.

HOLD

Current Price

$24.53

Market Cap

7.7B

Sector

N/A

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$8.67

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAE
IBRX
Founded
1947
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
8.2B
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
CAE
IBRX
Price
$24.53
$8.67
Analyst Decision
Buy
Strong Buy
Analyst Count
15
4
Target Price
★ $32.67
$14.25
AVG Volume (30 Days)
548.9K
★ 13.2M
Earning Date
11-10-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.71
EPS
★ N/A
N/A
Revenue
N/A
★ $113,288,000.00
Revenue This Year
$2.02
$99.98
Revenue Next Year
$1.83
$108.29
P/E Ratio
$35.13
★ N/A
Revenue Growth
N/A
★ 668.31
52 Week Low
$22.76
$1.95
52 Week High
$34.24
$12.43

Technical Indicators

Market Signals
Indicator
CAE
IBRX
Relative Strength Index (RSI) 55.75 45.48
Support Level $23.99 $6.68
Resistance Level $25.04 $9.54
Average True Range (ATR) 0.52 0.76
MACD 0.14 -0.19
Stochastic Oscillator 88.64 20.48

Price Performance

Historical Comparison
CAE
IBRX

About CAE CAE Inc.

CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: i) Civil Aviation: Provides comprehensive training solutions for flight, cabin, maintenance, ground personnel and air traffic controllers in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as airline operations digital solutions; and ii) Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: